Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, interventional, single-active-arm, single-center pilot study of mavrilimumab in patients with severe coronavirus 2019 (COVID-19) pneumonia and hyperinflammation

Next Previous
Search
Trial Profile

A prospective, interventional, single-active-arm, single-center pilot study of mavrilimumab in patients with severe coronavirus 2019 (COVID-19) pneumonia and hyperinflammation

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mavrilimumab (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 08 Jun 2020 According to a Kiniksa Pharmaceuticals media release, data from this trial was presented at the European E-Congress of Rheumatology (EULAR) 2020
    • 08 Jun 2020 Results published in Kiniksa Pharmaceuticals media release.
    • 29 May 2020 According to a Kiniksa Pharmaceuticals media release, data from this study will be presented at the at the European E-Congress of Rheumatology (EULAR) 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top